| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/24/2006 | DE102005006388A1 Replikationsdefiziente RNA-Viren als Impfstoffe Replication-deficient RNA viruses as vaccines |
| 08/24/2006 | CA2601924A1 Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
| 08/24/2006 | CA2598582A1 Use of nt-proanp/nt-probnp ratio for diagnosing cardiac dysfunctions |
| 08/24/2006 | CA2598535A1 Anti her2/neu antibody |
| 08/24/2006 | CA2598522A1 Human monoclonal antibodies to prostate specific membrane antigen (psma) |
| 08/24/2006 | CA2598292A1 Poly-epitope peptide derived from thymidylate synthase having immunological and anti-tumour activity |
| 08/24/2006 | CA2598290A1 Live attenuated rotavirus vaccine for oral administration |
| 08/24/2006 | CA2598090A1 Synergistic effect of tgf-beta blockade and immunogenic agents on tumors |
| 08/24/2006 | CA2598079A1 Adjuvant composition comprising aluminium phosphate and 3d-mpl |
| 08/24/2006 | CA2597933A1 Methods for treating lymphomas using a combination of a chemotherapeutic agent and il-2 and optionally an anti-cd20 antibody |
| 08/24/2006 | CA2597925A1 Use of human hemojuvelin product to regulate hepcidin-mediated iron metabolism |
| 08/24/2006 | CA2597924A1 Anti-cd19 antibodies and uses in oncology |
| 08/24/2006 | CA2597717A1 Antibodies against cxcr4 and methods of use thereof |
| 08/24/2006 | CA2597638A1 Methods for treating cancer using an immunotoxin comprising an exotoxin a moiety having a furin cleavage site replaced with a cancer-associated protease site cleaved by mmp-2 or mmp-9 |
| 08/24/2006 | CA2597373A1 Methods and compositions for impairing multiplication of hiv-1 |
| 08/24/2006 | CA2597263A1 Polypeptides from staphylococcus aureus and methods of use |
| 08/24/2006 | CA2596986A1 Use of il-17f in diagnosis and therapy of airway inflammation |
| 08/24/2006 | CA2596509A1 Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor |
| 08/24/2006 | CA2595939A1 Methods of predicting therpeutic response in atopic dermatitis to il-31 antagonists |
| 08/24/2006 | CA2595931A1 Methods of using death receptor agonists and egfr inhibitors |
| 08/24/2006 | CA2594490A1 Methods of treating skin disorders using an il-31ra antagonist |
| 08/24/2006 | CA2593643A1 A plasmodium vivax hybrid circumsporozoite protein and vaccine |
| 08/23/2006 | EP1693456A1 Gene encoding g protein-coupled receptor and gene product thereof |
| 08/23/2006 | EP1693448A1 Double specific antibodies substituting for functional protein |
| 08/23/2006 | EP1693385A1 Humanized anti-cd47 antibody |
| 08/23/2006 | EP1693384A2 Functional immunoglobulins against human serum albumin, fragments thereof, library thereof and methods of production thereof |
| 08/23/2006 | EP1693379A1 Protein nmb0928 and use thereof in pharmaceutical formulations |
| 08/23/2006 | EP1693378A2 Protein nmb1125 and use thereof in pharmaceutical formulations |
| 08/23/2006 | EP1693069A1 Remedy for solid tumor |
| 08/23/2006 | EP1693068A1 Use of M. tuberculosis chaperonin 60.1 for the treatment of arthritis |
| 08/23/2006 | EP1693067A1 Pharmaceutical anti-herpetic composition, method for producing a dosage form based thereon and method for the use thereof |
| 08/23/2006 | EP1693062A2 Androgen receptor-dependent gene expression control |
| 08/23/2006 | EP1692287A1 Bacterial virulence factors and uses thereof |
| 08/23/2006 | EP1692279A2 Preservative-containing virus formulations |
| 08/23/2006 | EP1692278A1 Hbv variants detection and application |
| 08/23/2006 | EP1692277A1 Methods and kits for predicting an infectious disease state |
| 08/23/2006 | EP1692269A1 Production of diphtheria toxin |
| 08/23/2006 | EP1692267A2 Methods of organ regeneration |
| 08/23/2006 | EP1692265A2 Method of preventing virus: cell fusion by inhibiting the function of the fusion initiation region in rna viruses having class i membrane fusogenic envelope proteins |
| 08/23/2006 | EP1692183A2 Chimeric anti cd44 antibodies and their use for treating acute myeloid leukemia |
| 08/23/2006 | EP1692182A2 Cd20 antibodies with increased fc receptor binding affinity and effector function |
| 08/23/2006 | EP1692176A1 Anti-igf-i receptor antibody |
| 08/23/2006 | EP1692175A2 Compositions and methods for regulation of tumor necrosis factor-alpha |
| 08/23/2006 | EP1692166A1 Novel muscle growth regulator |
| 08/23/2006 | EP1691891A2 Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure |
| 08/23/2006 | EP1691837A2 Ip-10 antibodies and their uses |
| 08/23/2006 | EP1691836A2 Anti-pecam therapy for metastasis suppression |
| 08/23/2006 | EP1691835A1 Methods of treating chronic pain using compositions that specifically bind cd11d (alpha-d) integrin |
| 08/23/2006 | EP1691834A2 Combination therapy |
| 08/23/2006 | EP1691833A2 Compositions comprising polypeptides |
| 08/23/2006 | EP1691832A2 Immunoglobulins whith potent and broad antiviral activity |
| 08/23/2006 | EP1691831A1 In ovo vaccination of campylobacter in avian species |
| 08/23/2006 | EP1691824A2 Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients |
| 08/23/2006 | EP1691746A2 Mucoadhesive drug delivery devices and methods of making and using thereof |
| 08/23/2006 | EP1691715A2 Surfactant-based gel as an injectable, sustained drug delivery vehicle |
| 08/23/2006 | EP1691664A2 Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof |
| 08/23/2006 | EP1691661A2 Soluble tcr molecules and methods of use |
| 08/23/2006 | EP1691615A2 Orally-administered live bacterial vaccines for plague |
| 08/23/2006 | EP1507794B1 Novel multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments |
| 08/23/2006 | EP1358318B1 Hybridoma cell line g250 and its use for producing monoclonal antibodies |
| 08/23/2006 | EP1240337B1 Methods and compositions for prolonging elimination half-times of bioactive compounds |
| 08/23/2006 | EP1178824B1 Staphylococcus aureus antigen-containing whole cell vaccine |
| 08/23/2006 | EP1051482B1 Cytotoxic heteromeric protein combinatorial libraries |
| 08/23/2006 | EP1012181B1 Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease |
| 08/23/2006 | EP0822831B2 Vaccines containing a saponin and a sterol |
| 08/23/2006 | CN1823163A Antibodies against insulin-like growth factor i receptor and uses thereof |
| 08/23/2006 | CN1823160A Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical proparations |
| 08/23/2006 | CN1823092A Therapy-enhancing glucan |
| 08/23/2006 | CN1822857A De-immunized anti-CD3 antibody |
| 08/23/2006 | CN1822856A HCV vaccines |
| 08/23/2006 | CN1822855A Avian e. coli vaccine for protection against colibacillosis |
| 08/23/2006 | CN1821411A Method for expressing hepatitis C virus envelope protein E2 by mammal cell with high efficient secretion |
| 08/23/2006 | CN1821410A Recombinant adenovirus containing codon optimized type IIPV16L1 gene |
| 08/23/2006 | CN1821407A High efficiency stable expression system of transgene tomato |
| 08/23/2006 | CN1821401A Method for obtaining functional protein fragment with independent structure |
| 08/23/2006 | CN1821385A Anthrax bacillus strain without pX01 and pX02 plasmid and its use |
| 08/23/2006 | CN1820784A Tobacco expressed foot-and-moath disease plant gene engineering vaccine and its preparing method |
| 08/23/2006 | CN1820734A Treatment with anti-erbb2 antibodies |
| 08/23/2006 | CN1271205C Reconstituted human anti-HM1.24 antibody |
| 08/23/2006 | CN1270775C Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enbancing agents |
| 08/23/2006 | CN1270774C Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| 08/23/2006 | CN1270773C Application of chitosan for preparing helicobacter pylorus vaccine adjuvant |
| 08/23/2006 | CN1270772C Anti-hepatitis-B-virus therapeutic vaccine and its adjuvant |
| 08/23/2006 | CN1270771C Influenza vaccine sucked or sprayed through nasal cavity, preparation method |
| 08/23/2006 | CN1270770C Polypeptide vaccine capable of effectively preventing pointed condyloma |
| 08/22/2006 | US7094946 Animal model for allergic disorders |
| 08/22/2006 | US7094887 UDP-N-acetylglucosamine: galactose-β1,3-N-acetylgalactosamine-α-R(GlcNAc to GalNAc) β1,6-N-acetylglucosaminyltransferase, C2GnT3 |
| 08/22/2006 | US7094884 A protein containing an amyloid beta (A beta ) peptide, a peptidyl prolyl isomerase chaperone,wherein the PrP and the peptidyl prolyl isomerase chaaperone are covalently linked, and such protein is soluble to at least 100 nM in a solution with a pH of 7.4 contains 20 nM sodium phosphate and 150 nM NaCl |
| 08/22/2006 | US7094883 Monoclonal antibody which agglutinates E. coli having the CS4-CFA/I family protein |
| 08/22/2006 | US7094879 Genetically engineered P30 antigen, improved antigen cocktail, and uses thereof |
| 08/22/2006 | US7094877 Protein for use in treatment of inflammation, nervous system, pain, arthritic and skin disorders |
| 08/22/2006 | US7094874 Soluble CTLA4 mutant molecules |
| 08/22/2006 | US7094757 diagnosis of transmissible spongiform encephalopathies (TSEs) especially in an immunoassay, as well as its use as an immunogen; genetic engineering |
| 08/22/2006 | US7094750 Toxin for use in treating cancer; antitumor agents |
| 08/22/2006 | US7094603 Transgenic human cells expressing superantigens/antiproliferative agents for use as gene therapeutic tools in cancer treatment ; tissue engineering |
| 08/22/2006 | US7094599 Therapeutic cells which express a membrane-bound, chimeric, proteinaceous receptor comprising an extracellular CD4 fragment to bind an HIV-infected cell without contracting the infection and an intracellular portion to destroy it |
| 08/22/2006 | US7094598 gene expression vectors comprising enhancers having sequence identity to dna sequences, that elicit immune responses against viral disease |
| 08/22/2006 | US7094597 Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis |
| 08/22/2006 | US7094587 16002 Molecules and uses therefor |
| 08/22/2006 | US7094577 Insulin and albumin fusion protein |